The Australian Clinical Trials Alliance (ACTA) is delighted to be holding the 2022 ACTA Annual Scientific Meeting including the Australian Registry Annual Scientific Meeting in-person from 7 – 8 November at the iconic SAHMRI in Adelaide.
About the ACTA ASM (in-person)
The ACTA ASM will be held on Tuesday 8 November with the theme – Implementing Evidence into Practice: how do we plan, engage and act to ensure our trials have the greatest impact and change practice. Implementation trials seek to determine the most effective way of translating knowledge into practice.
The meeting will include talks from regulators and government to hear how trialists, regulators and government can all work together to ensure quality evidence is generated and the translation into practice is fast and complete.
The ACTA ASM main keynote and panel discussion sessions will be held on Tuesday 8 November while workshops will be held on Monday 7 November.
You can choose 1 one-day workshop or 2 half-day workshops (in-person sessions).
About the Australian Registry ASM (in-person and online)
The Australian Registry ASM will be held on Monday 7 November with the theme – The Value of Registries in Challenging Times.
This event will aim to bring together Australian Registries, as well as governments, not for profits and other funders, and clinicians and health services. The meeting will be face-to-face and also have a small virtual component.
The program is currently being finalised and will include both invited speakers as well as presentations chosen from
Please visit the ACTA
website for more information.
Join the ASM social events
Along with the main meetings and workshops, we will also be holding three social events – a wine tour on Sunday afternoon 6 November, Australian Registry ASM Networking Cocktail on Monday early evening 7 November and an ACTA ASM dinner at the beautiful National Wine Centre of Australia on Monday evening 7 November.
IMPORTANT INFORMATION BEFORE YOU REGISTER:
All ACTA Members are entitled to a discounted member ticket rate for the ACTA ASM. ACTA Members include Individual Members and Members of any ACTA Member Organisations. Check if you are part of an ACTA Member Organisation here.
If you are interested in applying for an ACTA Membership, please visit the ACTA Membership page. Your membership application will need to be submitted and paid for before you can apply for a Member Ticket.
Sunday afternoon wine tour 6 November
***SEPARATE BOOKING IS NEEDED***
ACTA is organising a half-day wine tour for all delegates who would like to socialise prior to the event. Book here now.
The tour will be $98 pp and will include the following.
- Pick up from the Adelaide Convention Centre
- Expert Commentary by local Driver/Guide
- Woodstock Winery Wine tasting in the courtyard
- Beresford Estate tasting of premium wines
- Free time in McLaren Vale.
Please note all registrations require immediate payment by credit card. All credit card transactions will incur a surcharge of 1.75%. Payment by invoice may be possible at the organiser's discretion. Please contact the organiser at firstname.lastname@example.org
Thank you to our valuable Silver Sponsors
Exclusive Praxis Offer
Praxis Australia, in partnership with ACTA, is offering ACTA ASM attendees 20% off all PRAXIS Australia training offers, including Research Essentials, HREC Essentials and all Virtual Workshops. To help you meet your training needs for 2022, when you register for the ACTA ASM, you can gain access to expert-led online courses at an exclusive price – but only for a limited time.
The booking link and discount code will be sent to you with your ACTA ASM booking confirmation. Note: offer exclusive to ACTA ASM attendees. Only valid for enrolments received up until 8th November 2022.
Booking & Event terms and conditions
Download the full T&Cs here.
Please note all registrations require immediate payment by credit card. All credit card transactions will incur a
surcharge of 1.75%. Payment by invoice may be possible at the organiser's discretion. Please contact the organiser
ACTA gratefully acknowledges operational funding from the Australian Government’s Medical Research Future